Journal
BIOCHEMICAL PHARMACOLOGY
Volume 193, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2021.114787
Keywords
PEDF; Anti-tumor; Anti-metastasis; Cancer therapy; Drug resistance
Categories
Funding
- Curtin University RTP HDR Scholarship
Ask authors/readers for more resources
PEDF is a non-inhibitory member of the serpin family and is recognized as a potent anti-tumor factor in various cancers. Despite being considered an anti-metastatic marker in most studies, its role remains controversial with conflicting reports. This review systematically discusses the mechanisms and therapeutic effects of PEDF in tumor progression, aiming to enhance understanding in metastasis and drug development.
Pigment epithelium-derived factor (PEDF) is a non-inhibitory member of the serpin (serine protease inhibitor) family and is a well-known potent anti-tumor factor in a variety of cancers. It has been ascertained that PEDF regulates multiple metastatic processes through various plausible mechanisms, including inhibiting angiogenesis, inducing apoptosis, stimulating extracellular matrix (ECM) degradation, and suppressing the epithelial-tomesenchymal transition (EMT) process. Although PEDF has been recognized as an anti-metastatic marker in most studies, its role remains controversial with conflicting reports of PEDF as a metastatic marker. The emerging insights into the mechanism(s) of PEDF in tumor progression and its therapeutic effects are discussed systematically in this review, aiming to improve our understanding in the context of metastasis and drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available